Tumor circulome in the liquid biopsies for cancer diagnosis and prognosis

Wu, Jicheng; Hu, Shen; Zhang, Lihong; Xin, Jiaojiao; Sun, Chongran; Wang, Liquan; Ding, Kefeng; Wang, Ben

doi:10.7150/thno.40532

Cited by 105 publications

(68 citation statements)

References 141 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, the GNA of whole blood plasma or serum from over 1000 of patients has proven effective at detecting and predicting progression, reoccurrence, and/or survival in lung cancer [ 30 , 32 ] and bladder cancer [ 31 ]. The implementation of an additional EV isolation step prior to GNA has the potential to improve the clinical sensitivity and specificity of plasma glycan nodes as cancer biomarkers, as tumor-derived EVs play a critical role in cancer formation and progression [ 40 , 41 , 42 ], and can be detected in the circulation [ 43 ]. In this study, the quantitative consistency of plasma-derived EV glycan nodes in healthy donors and quantitative differences in glycan nodes in whole plasma vs. donor-matched plasma-derived EVs are reported, including a discussion of the reasons for and potential clinical implications of these results.…”

Section: Introductionmentioning

confidence: 99%

Glycan Node Analysis of Plasma-Derived Extracellular Vesicles

Walker

León

Busatto

et al. 2020

Cells

View full text Add to dashboard Cite

Blood plasma is a readily accessible source of extracellular vesicles (EVs), i.e., cell-secreted nanosized carriers that contain various biomolecules, including glycans. Previous studies have demonstrated that glycans play a major role in physiological and pathological processes, and certain plasma glycans have been associated with disease conditions. However, glycome studies have been limited by a lack of analytical techniques with the throughput capacity necessary to study hundreds of clinical samples. This study is the first to characterize the EV plasma glycome based on all major glycan classes. The results based on glycan node analysis revealed, as expected, that plasma-derived EVs have distinct glycan features from donor-matched whole plasma. Specifically, glycan nodes corresponding to those observed in chondroitin sulfate, dermatan sulfate, type I keratan sulfate, and type II keratan sulfate were enriched on EVs. The identification of specific differences in glycan features in plasma vs. plasma-derived EVs is relevant for understanding the physiological role of EVs and as a reference for future diagnostic studies. Additionally, the results indicate that EV glycan nodes do not substantially differ among a small set of healthy donors. These results lay the framework for the further evaluation of all EV glycan classes as diagnostic markers, therapeutic targets, and biologically active components in health and disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Glycan Node Analysis of Plasma-Derived Extracellular Vesicles

Walker

León

Busatto

et al. 2020

Cells

View full text Add to dashboard Cite

show abstract

“…Only when multiple genes including Myc and PVT1 are amplified at the same time can tumors occur. 104 The lncRNA PCGEM1 specifically expressed in prostate tissue is also located in the 8q24 region of the chromosome, which can bind with Myc protein, enhance the transcription of downstream genes by Myc, and promote the proliferation of prostate cancer cells. 105 …”

Section: Main Textmentioning

confidence: 99%

Targeting Long Non-coding RNA to Therapeutically Regulate Gene Expression in Cancer

Shi

Liu

et al. 2020

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Long-chain non-coding RNAs (lncRNAs) are RNA molecules with a length greater than 200 nt and no function of encoding proteins. lncRNAs play a precise regulatory function at different levels of transcription and post-transcription, and they interact with various regulatory factors to regulate gene expression, and then participate in cell growth, differentiation, apoptosis, and other life processes. In recent years, studies have shown that the abnormal expression of lncRNAs is closely related to the occurrence and development of tumors, which is expected to become an effective biomarker in tumor diagnosis. The sequencing analysis of mutations in the whole tumor genome suggests that mutations in non-coding regions may play an important role in the occurrence and development of tumors. Therefore, in-depth study of lncRNAs is helpful to clarify the molecular mechanism of tumor occurrence and development and to provide new targets for tumor diagnosis and treatment. This review introduces the molecular mechanism and clinical application prospect of lncRNAs affecting tumor development from the perspective of gene expression and regulation.

show abstract

“…The identification of new, highly sensitive, and specific tumor biomarkers is very important. The development of high-performance omic technologies, such as next generation sequencing, is a more efficient methodology that detects and characterizes genetic and molecular mutations, the decoding of genetic information is easier, faster, and less expensive for monitoring in time real of the disease, the objective is to establish the tumor profile for an early diagnosis that guides personalized therapeutic decisions with greater precision [18].…”

Section: Short Communicationmentioning

confidence: 99%

Liquid Biopsy: Theranostics and Personalized Oncology

Mali

Gosavi

Shukla³

2020

Innovare J Sci

View full text Add to dashboard Cite

Cancer is linked with mutated genes, and the study of tumor-associated genetic alterations is gradually used for diagnostic and treatment purposes. The solid tumors are now obtained from biopsy and/or surgical or biopsy specimens. Tumor cells release circulating free DNA into the blood, but the majority of circulating DNA are often not of cancerous origin, and the detection of cancer-associated alleles in the blood has long been unbearable to achieve. Modern science has overwhelmed these restrictions, making it possible to identify both genetic and epigenetic aberrations. A liquid biopsy (LB) or blood sample can provide the genetic landscape of all cancerous lesions (primary and metastases) as well as offering the opportunity to systematically track genomic evolution. This communication will explore how LB is associated with personalized oncology to predict response to treatments and the development of acquired resistance.

show abstract

Tumor circulome in the liquid biopsies for cancer diagnosis and prognosis

Cited by 105 publications

References 141 publications

Glycan Node Analysis of Plasma-Derived Extracellular Vesicles

Glycan Node Analysis of Plasma-Derived Extracellular Vesicles

Targeting Long Non-coding RNA to Therapeutically Regulate Gene Expression in Cancer

Liquid Biopsy: Theranostics and Personalized Oncology

Contact Info

Product

Resources

About